SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) was up 2.9% during trading on Friday . The company traded as high as $10.49 and last traded at $10.49, with a volume of 696,079 shares changing hands. The stock had previously closed at $10.19.

The stock has a market capitalization of $523.86 million and a PE ratio of 14.16. The company’s 50 day moving average price is $11.02 and its 200 day moving average price is $11.64.

SciClone Pharmaceuticals (NASDAQ:SCLN) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $0.20 earnings per share (EPS) for the quarter. The firm earned $39 million during the quarter, compared to analysts’ expectations of $37.90 million. Equities analysts expect that SciClone Pharmaceuticals Inc. will post $0.33 EPS for the current fiscal year.

In related news, CEO Friedhelm Blobel sold 501,875 shares of the business’s stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $10.00, for a total value of $5,018,750.00. Following the completion of the transaction, the chief executive officer now owns 588,255 shares of the company’s stock, valued at $5,882,550. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Wilson Wai-Shun Cheung sold 7,802 shares of the business’s stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $10.62, for a total transaction of $82,857.24. Following the completion of the transaction, the chief financial officer now directly owns 25,000 shares of the company’s stock, valued at approximately $265,500. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in SciClone Pharmaceuticals stock. Connor Clark & Lunn Investment Management Ltd. raised its position in SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) by 12.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 232,900 shares of the specialty pharmaceutical company’s stock after buying an additional 25,225 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.47% of SciClone Pharmaceuticals worth $2,143,000 as of its most recent SEC filing.

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.